FilingSEC EDGAR8-K
Oncolytics Biotech Announces Translational Data for Pelareorep in Anal Cancer Study
· SEC accepted
Filing content
The company reported that pelareorep combined with a checkpoint inhibitor showed immune activation and tumor shrinkage in anal cancer patients. Oncolytics is now seeking strategic partnerships to advance development.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…